MATTHEW DICKISON: Open Payments
NPI 1467794776 · HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$983 in 51 payments from 10 companies in 2025. Trend: 2023 $343 · 2024 $378 · 2025 $983
Food & beverage: $879Education: $104
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $302 |
| Janssen Pharmaceuticals, Inc | 13 | $177 |
| Braeburn Inc. | 1 | $130 |
| Alkermes, Inc. | 5 | $95 |
| Indivior Inc. | 4 | $88 |
| Neurocrine BioSciences, Inc. | 3 | $71 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Luye Pharma (USA) Ltd. | 1 | $19 |
Products named: UZEDY, INVEGA SUSTENNA, BRIXADI, ARISTADA, SUBLOCADE, INGREZZA, SPRAVATO, CAPLYTA.
Industry payments across CT — which companies pay providers there.
